GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today revealed final data from its Vivity ® Registry Study, which monitored ...

Alcon’s leading position in phacoemulsification for cataract surgery, with a 50% market share, helps pull in demand for standard intraocular lenses, or IOL, from bundling, and Alcon now holds a ...

GENEVA--(BUSINESS WIRE)-- Alcon (ALC), the global leader in eye care dedicated to helping people see brilliantly, announced today the introduction of Clareon ® PanOptix ® Pro intraocular lens (IOL) ...

GENEVA--(BUSINESS WIRE)-- Regulatory News: Alcon (ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that Vivity ®, the most widely implanted 9 extended ...

“Reaching the one million milestone for Vivity, the world's leading EDOF IOL, represents a meaningful achievement in restoring distance, intermediate and functional near vision for people worldwide, ...

Clareon PanOptix, which delivers exceptional clarity and offers spectacle independence across all distances with a patient satisfaction rate of 99.2%31-34; PanOptix® Trifocal IOL, implanted over 2.2 ...

“As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D—even with our leading products like PanOptix,” said Rob ...

†Compared to CENTURION and CONSTELLATION Vision Systems. Based on bench data. **Based on worldwide unit sales of AcrySof® IQ Vivity and Clareon Vivity IOLs, as of Q4, 2024. “As ophthalmic practices ...